Editor’s note: This is a developing news story. Please check back soon for updates.
Nanoscope Therapeutics submitted the first modules of a biologics license application for MCO-010, an investigational gene therapy to treat severe vision loss in retinitis pigmentosa, to the FDA, according to a press release.
This is the first biologics license application (BLA) submitted for a gene-agnostic gene therapy for retinal disease, with Nanoscope anticipating full submission by early 2026. The application was previously granted fast track designation and is eligible for priority review.
The BLA is